Finance

Lists
ZEAL:CPH
Zealand Pharma A/S
228,50 DKK
-1,21%
(-2,80) 1D
14 ოქტ, 11:47:37 GMT+2  ·   DKK
All symbols
SymbolPriceChange% Change
Generating top insights for ZEAL...
Open
232,00 DKK
High
234,60 DKK
Low
227,40 DKK
Mkt. cap
16,81 მლრდ.
Avg. vol.
402,85 ათ.
Volume
115,01 ათ.
52-wk high
556,00 DKK
52-wk low
227,40 DKK
Shares outstanding
71,61 მლნ.
No. of employees
578
Open
232,00 DKK
High
234,60 DKK
Low
227,40 DKK
Mkt. cap
16,81 მლრდ.
Avg. vol.
402,85 ათ.
Volume
115,01 ათ.
52-wk high
556,00 DKK
52-wk low
227,40 DKK
Shares outstanding
71,61 მლნ.
No. of employees
578
News stories
From web sources and news partners
Euronext Markets: Real-time Stock Market Data | live
Euronext Markets: Real-time Stock Market Data | live
·
12 საათის წინ
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion
Investing.com Canada
Investing.com Canada
·
13 საათის წინ
Zealand Pharma partners with Generate on AI drug development By Investing.com
Investing.com Canada
Investing.com Canada
·
13 საათის წინ
Generate Biomedicines, Zealand Pharma form AI drug partnership By Investing.com
Profile
Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018, they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley. Wikipedia
About Zealand Pharma A/S
CEOადამ შტინსბერგი
Employees578
Founded1 აპრ. 1997
Headquarters-
Sector-
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
49,57 მლნ.
68,92 მლნ.
34,00 მლნ.
4,49 მლრდ.
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
320,04 მლნ.
530,07 მლნ.
469,00 მლნ.
516,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
190,85 მლნ.
91,81 მლნ.
104,00 მლნ.
116,00 მლნ.
Operating expense
510,89 მლნ.
621,88 მლნ.
573,00 მლნ.
632,00 მლნ.
Total operating expenses
510,89 მლნ.
621,88 მლნ.
573,00 მლნ.
632,00 მლნ.
Operating income
-461,32 მლნ.
-552,97 მლნ.
-539,00 მლნ.
3,86 მლრდ.
Other non operating income
-17,59 მლნ.
-7,23 მლნ.
24,00 მლნ.
-91,00 მლნ.
EBT including unusual items
-366,73 მლნ.
-406,51 მლნ.
-394,00 მლნ.
4,01 მლრდ.
EBT excluding unusual items
-383,62 მლნ.
-460,20 მლნ.
-375,00 მლნ.
3,97 მლრდ.
Income tax expense
37,50 მლნ.
-27,39 მლნ.
-
89,00 მლნ.
Effective tax rate
-10,23%
6,74%
-
2,22%
Other operating expenses
-
1,00 ათ.
-
-
Net income
-404,23 მლნ.
-379,12 მლნ.
-394,00 მლნ.
3,92 მლრდ.
Net profit margin
-815,50%
-550,12%
-1 158,82%
87,22%
Earnings per share
-5,75
-5,19
-5,58
55,34
Interest and investment income
108,95 მლნ.
102,41 მლნ.
74,00 მლნ.
72,00 მლნ.
Interest expense
-7,00 მლნ.
-7,07 მლნ.
-5,00 მლნ.
-8,00 მლნ.
Net interest expenses
101,95 მლნ.
95,34 მლნ.
69,00 მლნ.
64,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-454,10 მლნ.
-550,48 მლნ.
-529,00 მლნ.
3,87 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები